Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.
In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in January.
The company reported £7.1mln of H1 2020 revenues on a reported basis, (no comparable revenues in H1 2019).
Price: 24.25 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH). Ulker talks through the prospects for the specialist pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals using human challenge studies. Ulker believes Open...
